SOUTH SAN FRANCISCO, Calif., June 5, 2017 /PRNewswire/ -- MiNDERA has been selected as a finalist for Red Herring's Top 100 North America award, one of the technology industry's most prestigious prizes.
Finalists for the awards are among the continent's brightest and most innovative private ventures. Their place among North America's tech elite has been chosen by Red Herring's editorial team, during a months-long process that takes into account criteria including disruptive impact, proof of concept, financial performance, market footprint and quality of management.
For over two decades Red Herring's team has seen through the tech sector's hype to select brands that have become industry benchmarks. Previous Top 100 finalists have included Alibaba, Facebook, Google, Skype, SuperCell, Spotify, Twitter, and YouTube.
"Selecting finalists for this year's Top 100 has proved more difficult than ever," said Alex Vieux, publisher and chairman of Red Herring. "North America has been tech's beating heart for years–but never have I seen such an exciting, disruptive and innovative generation as we have in 2017.
"MiNDERA fully deserves its place among our finalists, and I've every confidence it will make a significant impact in the tech world," added Vieux.
"This new recognition for MiNDERA means a lot to our team members. It is the result of their hard work and focus on transforming the way skin diseases are studied, diagnosed and treated. This comes on the heels of our successful clinical studies and poster presentation at SID 2017. We are looking forward to an exciting second half of the year with more important milestones for MiNDERA," said Philippe Nore, CEO and co-founder of MiNDERA.
MiNDERA will present at the Red Herring Top 100 North America conference in Los Angeles on June 13, 2017. The Top 100 winners will be announced at a special awards ceremony on the evening of June 14 at the event.
MiNDERA is a San Francisco Bay area VC-backed company developing non-invasive, high precision genomic tools for skin diseases (oncology, inflammatory diseases). Our minimally invasive micro-needle device extracts the whole transcriptome from the skin of patients, eliminating the need for clinical researchers to source skin biopsies, a major pain point in dermatology research. Our technology, coupled with NGS, enables large-scale genomics studies with data from thousands of samples instead of dozens today. Our technology has already attracted the interest of large customers with several signed collaborations with global Pharma and Skin Care leaders.
SOURCE MiNDERA Corp.